RT Journal Article
SR Electronic
T1 Nontuberculous mycobacteria lung infection in bronchiectasis: Prevalence and clinical characteristics
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2483
VO 44
IS Suppl 58
A1 Jin-Fu Xu
A1 Xiao-bin Ji
A1 Li-chao Fan
A1 He-ping Xiao
A1 Hai-Wen Lu
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2483.abstract
AB The prevalence, risk factors and clinical features of bronchiectasis with NTM lung infection in China remain unclear. Retrospective analysis of patients diagnosed as bronchiectasis or bronchiectasis with NTM lung infection(NTMLI) from January 2009 to December 2012 in a tertiary hospital. The demographic data, risk factors and clinical characteristics data were concluded and comparatively analyzed. Systematic analysis was performed in 192 cases who diagnosed as bronchiectasis with NTMLI. The number of patients with bronchiectasis was 3,857 cases. Patients with ultimate diagnosis of bronchiectasis with NTMLI were 192 cases, accounting for 4.98%. The sex ratio of bronchiectasis with NTMLI group was 1:2.1. The percentages of past history of pulmonary tuberculosis in bronchiectasis patients with or without NTMLI were significantly different (16.7% vs. 28.8%). The proportion of history of long-term use of immunosuppressive agents in bronchiectasis with NTMLI patients (11.5%) was significantly higher than that in bronchiectasis patients (5%). There are no differences on age, smoking history and history of diabetes between two groups. 24.3% of the bronchiectasis with NTMLI patients showed CD4 + T/CD8 + T cell ratio decreased. The positive rates of blood interferon gamma release assay (IGRA/T-SPOT) test in bronchiectasis with NTMLI patients were low. The separation rate of other bacteria in bronchiectasis with NTM lung infection (14.1%) was lower than that in bronchiectasis patients (24.5%). Women, long-term use of immunosuppressive agents in bronchiectasis patients were prone to accompany NTM lung infection. For susceptible patients, doctors should take the initiative to screen NTMLI.